Mps bay2a

The drugs used for screening in this study are listed in Supplementary Table 1.
Reversine, SP600125, ZM 447439, BI 2536, STLC, Dimethylenastron, SB203508, RO 3306, Cdk1 Inhibitor III, Roscovitine, NSC 95397, IPA3, Y-27632, ITX-3, Nocodazole, Paclitaxel, Blebbistatin, Cytochalasin B, MG 132 and Velcade were purchased from Sigma–Aldrich (St. Louis, MO, USA). AZ 3146 and Mps-BAY2a were obtained from Tocris (Bristol, United Kingdom). MLN8237 (Alisertib), AZD1152-HQPA (Baraserib) and SB743921 were purchased from Selleckchem. GSK923295 is from MedChem express.
Monoclonal antibodies against α-tubulin, CDK1, AURKA, PLK1, KIF11 (Sigma-Aldrich); CCNB1, CCNE1, TP53, CDKN1A, JNK1, JNK2 (Cell signaling); EB1, COFILIN (Santa Cruz), TTK, BUBR1 (Abcam). Polyclonal antibodies against PRC1 (Santa Cruz), Tpx2 [69 (link)]; Kif23 [70 (link)] were used.

Reversine (BioNordika, Stockholm, Sweden), Mps-BAY2a (Tocris Bioscience, Bristol, UK), were stocked as 10 mM solution in DMSO. The pan-caspase inhibitor z-VAD-fmk (Sigma-Aldrich, Germany) was stocked as a 50 mM. The necroptosis inhibitor Necrostatine-1 (Sigma-Aldrich, Germany) was stocked as a 100 mM. The appropriate amount of DMSO or ethanol was always employed for negative control conditions.